Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending January 2013, with the announcement issued on January 9, 2013. The filing reports a strategic regulatory milestone in collaboration with Theravance, Inc. regarding the development of respiratory medicines for chronic obstructive pulmonary disease (COPD).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory announcement regarding product development and does not contain financial statements or performance metrics.
Material Changes and Developments
- European Regulatory Submission: GSK and Theravance submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for ANORO™ (UMEC/VI), an investigational once-daily LAMA/LABA combination medicine.
- Product Details: The submission covers doses of 55/22mcg and 113/22mcg (delivered doses) for maintenance bronchodilator treatment in adult COPD patients.
- US Context: This follows a regulatory application submission in the United States on December 18, 2012, for the same product.
- Portfolio Expansion: GSK plans to commence global regulatory submissions for UMEC monotherapy later in 2013 and has other late-stage respiratory assets in development, including fluticasone furoate/vilanterol (FF/VI).
Guidance, Outlook, and Risks
Outlook: Regulatory submissions for UMEC/VI are planned for other countries during 2013. GSK intends to submit for UMEC monotherapy globally later in the year.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers for both GSK and Theravance. Key risks cited include:
- Potential clinical or non-clinical study results indicating product candidates are unsafe or ineffective.
- Delays or failure to achieve regulatory approvals.
- Risks associated with reliance on third-party manufacturers and collaborators.
- Changes in circumstances or assumptions that could cause actual results to differ materially from projections.
Unusual Items: None reported in this filing.
Investor Verification Checklist
- Verify the status of the EMA review process for ANORO™ (UMEC/VI) following the January 2013 submission.
- Monitor the timeline for the planned global regulatory submissions for UMEC monotherapy.
- Review the progress of other late-stage respiratory assets mentioned, specifically FF/VI (RELVAR™/BREO™) and MABA.
- Assess the commercial partnership terms and milestones between GSK and Theravance regarding these respiratory programs.